256 related articles for article (PubMed ID: 21781226)
1. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A
Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
[TBL] [Abstract][Full Text] [Related]
8. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
10. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
12. New approved dasatinib regimen available for clinical use.
Snyder DS
Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
Somlo G; Atzori F; Strauss LC; Geese WJ; Specht JM; Gradishar WJ; Rybicki A; Sy O; Vahdat LT; Cortes J
Clin Cancer Res; 2013 Apr; 19(7):1884-93. PubMed ID: 23403636
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib in solid tumors.
Kim LC; Rix U; Haura EB
Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
17. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Molife LR; Dean EJ; Blanco-Codesido M; Krebs MG; Brunetto AT; Greystoke AP; Daniele G; Lee L; Kuznetsov G; Myint KT; Wood K; de Las Heras B; Ranson MR
Clin Cancer Res; 2014 Dec; 20(24):6284-94. PubMed ID: 25278451
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
